MML Investors Services
ASND icon

MML Investors Services’s Ascendis Pharma A/S ASND Stock Holding History

MML Investors Services’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,644
Closed -$226K – 2688
2024
Q4 		$226K Buy
+1,644
New +$216K ﹤0.01% 2440

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MML Investors Services's ASND Position: Q1 2025 in Review

MML Investors Services sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 1,644 shares — an estimated $226K sold.

MML Investors Services first reported a position in ASND in Q4 2024 and held it in 1 quarter. The position peaked at $226K in Q4 2024. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

  • MML Investors Services reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
  • MML Investors Services sold 1,644 Ascendis Pharma A/S shares in Q1 2025, an estimated $226K.
  • MML Investors Services first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 1 quarter.
  • MML Investors Services's Ascendis Pharma A/S position peaked at $226K in Q4 2024.
  • 244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on MML Investors Services's 13F filing for Q1 2025, filed 14 May 2025.